Ascendis Pharma A/S Receives Orphan Designation for TransCon™ PTH for Treatment of Hypoparathyroidism in Europe
October 23, 2020
COPENHAGEN, Denmark, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address
Related News
Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the American Society of Nephrology Kidney Week
Oct 22, 2020 Press Release for Alnylam Alnylam Presents Positive Results from ILLUMINATE-B Phase 3 Study in Pediatric Patients with Primary Hyperoxaluria Type 1 at the...
Public Technologies 2020-10-22The global market for Osteoporosis Therapeutics is projected to reach US$13.3 billion by 2025
NEW YORK, Oct. 21, 2020 /PRNewswire/ -- The global market for Osteoporosis Therapeutics is projected to reach US$13.3 billion by 2025, driven by rising awareness over the...
The Oneida Daily Dispatch
2020-10-21
Lantern Pharma to Host Third Quarter 2020 Operating and Financial Results Conference Call on October ...
DALLAS, Oct. 22, 2020 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.")...
Odessa American
2020-10-22
Retrophin Announces Agreement to Acquire Orphan Technologies
Agreement addsOT-58, a novel enzyme replacement therapy in Phase 1/2 development forthe treatment ofclassical homocystinuria Compellingstrategic fit thatwillexpand...
Tyler Morning Telegraph
2020-10-22
Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera
NEWARK, Calif., Oct. 21, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that the European Medicines Agency (EMA) has granted orphan drug...
PR Newswire 2020-10-21Adaptive Phage Therapeutics Receives Orphan Drug Designation for PhageBank™ in Prosthetic Joint Infections
GAITHERSBURG, Md.--(BUSINESS WIRE)--Oct 22, 2020-- Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat the...
The Marshall News Messenger
2020-10-22
Priority Review Granted to Ascentage Pharma's New Drug Application for Olverembatinib (HQP1351), the First Third-Generation ...
SUZHOU, China and ROCKVILLE, Md., Oct. 21, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing...
Herald Mail
2020-10-21